NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’
For industry, the sole health agency head held over from the Obama Administration means the ‘Moonshot’ priorities will move forward – and one possible threat to pricing is cut off.
You may also be interested in...
Norman Sharpless, director of the National Cancer Institute, will become acting FDA commissioner when Scott Gottlieb departs.
Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas
Last week’s US House and Senate hearings on drug pricing underscore how quickly the negative attention has turned to industry. With more public discussions planned – including potential testimony from pharma execs – here’s what can be expected in the months ahead.
Perspectives on two individuals – James O’Neill and Balaji Srinivasan – under review for potential high-level posts at the US agency, plus lessons learned from how FDA topsiders have been selected in the past.